With another win, Bayer and Johnson & Johnson are now three for three in fending off lawsuits over the bleeding risks of blockbuster Xarelto.
One cancer patient is urging Novartis to weigh taxpayer investment in early-stage CAR-T science in setting a price on its new med tisagenlecleucel.
Look who’s talking—to voice assistants. Physicians are increasingly adopting the hands-free, time-saving tools.
In a Sanofi ad agency rejig, the WPP Group joins Publicis and Havas as creative and media agencies across the company's business units.
Remember Doan’s for back pain? It's back, thanks to Dr. Reddy’s Laboratories, which is breathing new marketing life into a handful of older brands.
Pfizer has rebuked U.K. drug cost watchdog NICE for its refusal to recommend approval of the drugmaker's new targeted leukemia treatment.
Merck CEO Ken Frazier's resignation from President Trump’s manufacturing council has resonated positively across a broad audience.
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
Sorry, Tesaro. AZ's Lynparza won a broader-than-expected approval in ovarian cancer, putting it on even footing with Tesaro’s recent launch, Zejula.…
Reps. Elijah Cummings and Peter Welch announced a new probe into multiple sclerosis drug costs, digging into price hikes from seven pharmas.